Navigation Links
NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
Date:12/29/2008

s is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and include specifically the reference in this press release to increased revenues through the DynaClub direct sales program and the reference to restoring profitability. Such statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2008.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
2. Memory Pharmaceuticals Regains Compliance with NASDAQ Market Capitalization Requirement
3. Mylan Announces Move to NASDAQ Stock Market
4. DATATRAK International, Inc. Receives Notice from NASDAQ
5. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
6. Memory Pharmaceuticals Receives NASDAQ Decisions
7. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
10. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
11. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily ... FDA clearance for results that last for two years, the longest of any cellulite ... who are looking for a long-lasting, effective solution for their cellulite, according to Dr. ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint ... grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in a ... for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest ... Work in Healthcare by Modern Healthcare and will be honored at an awards ... eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers in ...
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars afford ... with practice contact information and logos, Calendars stand alone as functional brand-building ... into seasonal mailings, thank you and welcome communications, and to complement statements and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® ... Thermal Flavor Extraction™ technology, which delivers a variety of sizes and styles while ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... may potentially play a role in the maintenance of ... a recent issue of Nutrition in Clinical Care. The ... on risk factors for heart disease. Several studies suggest ... and blood pressure. It may also help keep blood ...
... doses of painkillers to ease the agony of terminally ... have criticized the practice, comparing it to euthanasia, but ... receiving higher doses of drugs such as morphine live ... , ,In research published in The Lancet medical journal, ...
... children with autism. Antibiotcs seem to treat or prevent the ... every 150 children is affected by autism. Currently there are ... Hospital in Chicago found that a subset of patients with ... can be helped by antibiotic vancomycin. ,Interestingly the ...
... The discovery of the gene associated with the inherited form ... of Columbia University and James A. Knowles of the Columbia ... study, funded in part by the National Heart, Lung, and ... in the September issue of the American Journal of Human ...
... when given to children with diarrhea caused by ... increased risk of developing a serious condition known ... website of The New England Journal of Medicine ... children after a gastrointestinal infection, begins with vomiting ...
... and Blood Institute (NHLBI) and the National High Blood ... to treat Hypertension.,Control of systolic blood pressure is as ... a crucial message for health care providers, patients, and ... systolic blood pressure to less than 140 mm Hg ...
Cached Medicine News:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... RATON, Fla., Sept. 15 Watermark Medical , ... the sleep-disordered breathing market, has expanded the market reach ... strategic alliances with three leading sleep solution providers in ... SleepQuest , a national provider of comprehensive sleep apnea ...
... Sept. 15 ViroPharma Incorporated (Nasdaq: VPHM ... Phase 1 study of VP20621 (non-toxigenic Clostridium difficile ... Clostridium difficile infections (CDI), a common and dangerous ... of antibiotic medications.  VP20621 contains the spores of a ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 2ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 3ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 5ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 6
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits ... mixture of lipid antigens, which will ... serum or plasma. The particles are ... to eliminate non - specific reactions. ...
... a quality assurance reagent in assays detecting ... (TOXO IgG and TOXO IgM), IgG and ... and rubella IgM), IgG and IgM antibodies ... and IgG antibodies to herpes simplex virus ...
... The Diamedix Immunosimplicity (Is) Rubella ... procedure,intended for the qualitative and quantitative ... test can be performed either manually ... Automated EIA Processor. The results are ...
Medicine Products: